

Heterogeneous catalytic hydrogenations in flow – routes to scale-up

Martin Monedero
martin.monedero@amt.uk
www.amt.uk



Introduction



AM Technology manufacture Coflore flow reactors

Founded in 2000

Mr Robert Ashe & Mr David Morris
Ashe Morris Ltd

UK Headquarters


Based in the North West, between Liverpool and Manchester

Multidisciplinary Team

Experienced team comprising of chemical, mechanical, electrical engineers and chemists.

R&D Facilities

Flow feasibility studies
Process development - lab to pilot
Engineering design



Why Batch?

Batch Reactors:

Simple:

Material is located in one place
Established 'one-pot' synthesis familiar to chemists

Multi Purpose:

Can be used with multiphase reactions
Various recipes with same equipment

Scalable:

Different sizes enable scale up to large volume manufacture
Well-established scaling parameters



Where Are The Issues?

Typical 1,000 L Batch Operation Steps

Charge Vessel

Addition of solvent/reagents and
inertion cycles - can be slow

Temperature Control

Heat up or cool down of large reactor
volumes - Large peak utility power
requirements

Exotherm? Dropwise

Addition...

Very time-inefficient

Reaction Time

What may take 5 minutes in a 10 mL
flask could take 10 hours in a 1,000 L
reactor

Equipment Cleaning

Required after every 1,000 L
production

Reactor Downtime

Between each run

Capacity Utilisation: The % that plant capacity is used vs the theoretical maximum

Continuous manufacturing can reduce some or all of these process inefficiencies

Why Manufacture in Flow?

THE WALL STREET JOURNAL.

| LEADER (U.S.)

New Prescription For Drug Makers: Update the Plants

After Years of Neglect, Industry Focuses On Manufacturing; FDA Acts as a Catalyst

By Leila Abboud and Scott Hensley Staff Reporters of The Wall Street Journal

Updated Sept. 3, 2003 12:01 a.m. ET

G.K. Raju, an expert in pharmaceutical manufacturing at Massachusetts Institute of Technology who advises drug makers and has visited many plants. Quality testing is done by hand. Computerized equipment and robots aren't as common as in other high-tech industries. One sign of inefficiency: Vats, blenders and presses in factories often sit idle.



Guidance for Industry

PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance

Pharmaceutical CGMPs
September 2004


Facilitating continuous processing to improve efficiency and manage variability
For example, use of dedicated small-scale equipment (to eliminate certain scale-up issues)



For Immediate Release: February 26, 2019

Statement From: Scott Gottlieb, M.D.

One of today's most important tools for modernizing the pharmaceutical industry is a process known as continuous manufacturing (CM). This approach transforms the



A.C. Fisher, W. Liu, A. Schick, M. Ramanadham, Sharmista Chatterjee, R. Brykman, S.L. Lee, S. Kozlowski, A.B. Boam, S.C. Tsinontides, M. Kopcha, *Int. J. Pharm.*, 2022, 622, 121778.

Challenges in Flow - Solids

Avoidance


Solvent selection
Dilution
Homogeneous catalysis

Immobilisation

Packed bed, fluidised bed
Catalytic solids
Highly dedicated plant


Slurries

Static mixers, mechanical mixers
Dependent on flow regime and channel size
How to trial at lab-scale



Packed bed


Fluidised bed



Continuously Stirred Tank Reactor (CSTR)



Agitated Cell Reactor (ACR)



Agitated Tube Reactor (ATR)

Challenges in Flow - Solids

Avoidance

Solvent selection
Dilution
Homogeneous catalysis

Immobilisation


Packed bed, fluidised bed
Catalytic solids →
Highly dedicated plant

M. Irfan, T.N. Glasnov, and C.O. Kappe, *ChemSusChem*, **2011**, 4, 300 – 316


K. Masuda, T. Ichitsuka, N. Koumura, K. Sato, S. Kobayashi, *Tetrahedron*, **2018**, 74, 1705-1730

Slurries


Static mixers, mechanical mixers
Dependent on flow regime and channel size
How to trial at lab-scale



Packed bed




Fluidised bed



Continuously Stirred Tank Reactor (CSTR)



Agitated Cell Reactor (ACR)



Agitated Tube Reactor (ATR)

O. Levenspiel, *Chemical Reaction Engineering*, Wiley, New Delhi, 3rd edn., 2016

H.P. Rice et al., *Chem. Eng. Process*, 2022, **179**, 109067.

Challenges in Flow - Slurries

Issue


Solution

Bridging




Increase Channel size

Settling



Increase Turbulence*

Fouling



Increase Wall Shear




***Through high fluid velocity
or mechanical mixing**

Challenges in Flow - Immobilisation

Packed Bed reactors are the most common form of Immobilised solids in flow.

Oversize to overcome drop in conversion:

- Increase detrimental side reactions
- Increase pressure drop
- Cost impact on peripheral equipment




Dudukovic et. al, Multiphase Catalytic Reactors: A perspective on Current Knowledge and Future Trends, 2007.

Challenges in Flow - Comparison


Slurry Fed Reactors		Packed Bed Reactors
Blockages always possible	Reliability	Low chance of blockages
Indefinite processing	Run Length	Shutdowns necessary
Large peripheral equipment	Footprint	Oversizing common
Only affected by conditions	Product Consistency	Conversion affected by run length
Catalytic and stoichiometric solids	Versatility	Limited to catalytic solids
High filtration requirements	Downstream Processing	Often only clarification

Case Study



Reduction of Quinuclidinone in the Coflore ACR



3-Quinuclidinone



3-Quinuclidinol




Solifenacin



Catalysis 3-ways


1) Slurry Feed - Biocatalyst



2) Slurry Feed - Pd/C Paste



3) Immobilised - Pd/C Pellets



Biocatalytic Reductions



Black Powder Biocatalysts

Little to no experience with enzymes

Established experience with enzymes


Complete solutions
'Slot in' alternatives to supported metal catalysts
(low barrier-to-entry, no new knowledge or infrastructure required)

New ways of working
Use your own proprietary enzymes
(less waste, less complicated, continuous manufacturing)

Energy & resource
efficiency

Continuous
manufacturing

Circular / bio-based
economies



Martin Monedero | martin.monedero@amt.uk | www.amt.uk





Contact
Holly Reeve, CEO
Sarah Cleary, CSO
T: +44 1865 309651,
E: sarah@hydregenoxford.com
W: hydregenoxford.com

Biocatalytic Reductions

Black Powder Biocatalysts




Asymmetric C=X hydrogenations




Swap in any NADH-dependent enzyme

Case examples:




typically >99 % ee

Selective nitro to amine hydrogenation



Case examples:



- **Batch** and **continuous** reactors
- Simple catalyst removal/**reuse**
- **Scale-up** strategies




- Multi-day **stability**
- **Mild** conditions
- High yields, low waste

- Enzyme **selectivity** retained
- Functional group tolerance (halogen, sulphur, etc.)
- Replaces precious metals



Nitro or azide reductions: Manuscript in prep, get in touch for info!

Selective C=X reductions: H. A. Reeve *et al.*, *ChemCatChem* **2015**, *7*, 3480. | B. Poznansky *et al.*, *Front. Chem. Eng.* **2021**, *3*, 35. | S. E. Cleary *et al.* *Front. Catal.* **2023**, *3*, 1114536.

Comparison of catalysts

	Biocatalyst 	Pd/C Paste 	Pd/C Pellets 
Active Site Loading	~25% Enzyme	5% Pd/C	1% Pd/C
Catalyst Loading	0.15 mg / mL	0.15 mg / mL	0.96 g / 5.34 g
Particle size	20 - 50 nm	< 100 μm	1 - 3 mm
Specific surface area	1272 m^2/g	800-1000 m^2/g	941 m^2/g

Setup Overview




All tests conducted in the same setup;

- 0.4 to 3 mL/min slurry feeding
- 15 to 108 minute liquid phase residence time

Setup Obstacles

Diaphragm Pump



- High Pressure
- Scalable to higher Flows
- Integral Check valves


149 μm Activated Carbon



20 - 50 nm Biocatalyst



Peristaltic Pump



- Low - Mid Pressure
- High Turndown of low flows
- Material Compatibility


149 μm Activated Carbon




20 - 50 nm Biocatalyst



Biocatalyst results




Assuming a 0th order reaction,
full conversion in ~74 minutes
35 °C, 2 Bar



System operated for >100 hours

$\text{TOF}_{15} = 286 \text{ min}^{-1}$	-15 minute Residence time
$\text{TOF}_{54} = 161 \text{ min}^{-1}$	-54 minute Residence time
$\text{TOF}_{108} = \geq 152 \text{ min}^{-1}$	-108 minute Residence time



Immobilised Catalyst results




	Constant surface area scaled	Packed Catalyst Baskets
Catalyst Mass (g)	0.96	5.34
Reactor Volume (mL)	78	68
Residence time (min)	56	56
Conversion (%)	16 - 17	100
Pd TOF (min^{-1})	0.16	≥ 0.05
Pressure (bar)	10	10



Comparison & Conclusion


- Versatility is key. Same process design, different processes.
- Bio-catalyst offers a "Slot in alternative".
- Scale-down approach




	Highest observed TOF	Conditions used for TOF
 Slurry Biocatalyst	261 min ⁻¹	35 °C, 2 Bar
 Slurry Pd/C Paste	<0.01 min ⁻¹	35 °C, 2 Bar
 Immobilised Pd/C Pellets	0.16 min ⁻¹	35 °C, 10 Bar

Next Steps


- Intensification of biocatalysis process
- Inline analytical development
- TOF vs. time for pellets vs. biocatalyst
- Scaleup - 10 L flow trials ongoing
- Downstream processing
- Final skid design



Agitated Tube Reactor (ATR)



Turbulent Radial Mixing
Axial Plug Flow



Thank You



AM Technology
Engineering Chemistry

Martin Monedero
martin.monedero@amt.uk

Dr Mike Kenny
michael.kenny@amt.uk



30 - 90 mL



0.35 - 10 L



100 L



Dr Sarah Cleary
sarah@hydrogenoxford.com

Dynamically-mixed flow reactors